156
Participants
Start Date
October 10, 2017
Primary Completion Date
February 28, 2023
Study Completion Date
December 31, 2027
Osimertinib
Osimertinib 60 or 40 mg daily until progression
Gefitinib
Gefitinib 250mg daily until progression
Institut Bergonie, Bordeaux
CHU de Brest, Brest
Centre Francois Baclesse, Caen
Centre Hopitalier Intercommunal De Creteil, Créteil
Assistance Publique - Hopitaux de Marseille - Hopital Nord, Marseille
Institut Paoli-Calmettes, Marseille
Centre Paul Strauss, Strasbourg
CHU Toulouse - Hopital Larrey, Toulouse
Institut de Cancerologie de Lorraine, Vandœuvre-lès-Nancy
Gustave Roussy, Villejuif
King Hussein Cancer Center, Amman
Medical University of Gdansk, Gdansk
University Clinic Golnik, Golnik
The Institute Of Oncology, Ljubljana
University Hospital A Coruna-Hospital Teresa Herrera, A Coruña
Hospital Clinic Universitari de Barcelona, Barcelona
Hospital De La Santa Creu I Sant Pau, Barcelona
Vall d'Hebron Institut d'Oncologia, Barcelona
Hospital Universitario 12 De Octubre, Madrid
Hospital Universitario Ramon y Cajal, Madrid
Institut Catala d'Oncologia - ICO Badalona - Hospital De Mataro, Mataró
Virgen del Rocio University Hospital, Seville
Collaborators (1)
AstraZeneca
INDUSTRY
European Organisation for Research and Treatment of Cancer - EORTC
NETWORK